A new molecular imaging agent

.
Alzheimer's Donation
Donate Online Now
.


MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals used in molecular medicine, has entered into a collaboration agreement with Avid Radiopharmaceuticals Inc. to support clinical studies for Avid's novel radiopharmaceuticals designed to diagnose and monitor Alzheimer's disease. These trials will use advanced molecular imaging known as single photon emission computed tomography (SPECT). Under the terms of the agreement, MDS Nordion will radiolabel Avid's proprietary compounds for use in proof-of-concept clinical trials for SPECT imaging of Alzheimer's disease.
According to the Alzheimer's Association, there are approximately 5 million people in the United States who suffer from Alzheimer's disease. As the population ages that number is expected to grow significantly. Meanwhile, the costs associated with the disease are considerable. The Alzheimer's Association estimates that the direct and indirect costs for treatment and care of Alzheimer's patients in the United States alone is US $148 billion annually.
"This partnership with Avid provides an exciting opportunity to develop a new molecular imaging agent that can assist researchers to identify a more effective therapy for patients with this debilitating disease," said Steve West, President of MDS Nordion. "MDS Nordion is using its proprietary technologies to work to develop these important compounds with our pharmaceutical and bio-pharmaceutical partners."

More support for prebiotic, probiotics for colon health
Daily intake of prebiotics and probiotics may reduce the production of potentially toxic or carcinogenic compounds by suppressing the activity of certain enzymes, says new research from Belgium ...